For patients with non-favorable risk AML and NPM1 mutation, the ALFA-0702 trial found that allo-HSCT improved disease-free survival (HR 0.25) and overall survival (HR 0.25) in patients with less than 4-log reduction in NPM1 MRD after initial chemotherapy [69]. This evidence concerns the gene NPM1 and acute myeloid leukemia.